AB Science provides an update on its clinical development program.

About this update from Alliancebernstein Holding L.p.

PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON ITS CLINICAL PROGRAM THE POLICY COVERS UP TO EUR 25 MILLION OF TRIAL COSTS IN THE EVENT OF CLINICAL FAILURE, WITH ZERO DEDUCTIBLE THIS RISK-TRANSFER STRUCTURE PROTECTS SHAREHOLDER CAPITAL AND SIGNALS INSTITUTIONAL CONFIDENCE IN THE MASITINIB PROGRAMME Paris, April 16, 2026, 7pm CET AB Science SA (Euronext - FR0010557264 - AB) provides an update on its clinical development program. Insurance for phase 3 in ALS AB Science has received a binding offer for a Clinical Trial Funding Insurance policy from Medical & Commercial International Ltd. (MCI), Lloyd’s Syndicate 1902, for its Phase III clinical trial AB23005, evaluating masitinib (AB1010) as an add-on therapy in Amyotrophic Lateral Sclerosis (ALS). The policy, effective from the date the first patient is enrolled, provides coverage for a limit of liability of EUR 25,000,000 and potentially up to EUR 39,000,000 against the full financial cost of clinical failure, with no deductible. This placement was arranged by Lloyd’s broker Acrisure Re UK, in conjunction with its European affiliate, Acrisure Re Netherlands. Clinical Trial Funding Insurance (CTFI) is a specialized financial product that reimburses a biopharmaceutical company for the costs incurred in running a clinical trial, in the event that trial fails to meet its pre-defined, policy specific, success criteria (often aligned to the trial protocol end points). Phase III programs — the pivotal, large-scale studies required before regulatory approval — typically cost millions of euros and can fail for reasons entirely outside a sponsor’s control, including lack of efficacy, unexpected safety findings, regulatory actions, or supply chain disruptions. CTFI allows AB Science to transfer a significant portion of this financial risk to MCI in exchange for a one-time up-front premium. The delivery of a CTFI binding quotation has been possible through MCI’s thorough diligence process reviewing past clinical data, real-life data, trial design and in-silico modelling. The CTFI will become effective (and the premium will be payable) when AB Science are ready to initiate its ALS Phase III clinical trial, and when AB Science will have mobilized the necessary financing for such study and the payment of the premium. The CFTI offer received is binding and may be activated until December 31st, 2026. Alain Moussy, CEO a...

View stock analysis, news, and events for Alliancebernstein Holding L.p.